Innate Pharma S.A. (EPA:IPH)

Innate Pharma Revenue

Innate Pharma had revenue of 5.66M EUR in the half year ending June 30, 2026, a decrease of -54.13%. This brings the company's total for the last twelve months to 9.81M, down -22.38% year-over-year. In the year 2025, Innate Pharma had annual revenue of 9.01M, down -55.25%. That makes Innate Pharma the 36,874th largest company in the world by revenue and 476th in France.

• Revenue (ttm): 9.81M
• Revenue Growth: -22.38%
• P/S Ratio: 12.46
• Revenue / Employee: 81.73K
• Employees: 120
• Market Cap: 122.19M

Revenue Chart

Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	9.01M	-11.12M	-55.25%
Dec 31, 2024	20.12M	-41.52M	-67.36%
Dec 31, 2023	61.64M	3.97M	6.88%
Dec 31, 2022	57.67M	32.97M	133.47%
Dec 31, 2021	24.70M	-45.07M	-64.60%
Dec 31, 2020	69.77M	-15.68M	-18.35%
Dec 31, 2019	85.45M	-	-

Data Source: Fiscal.ai Last updated: Jun 30, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 18, 2026

Data Sources Report a data error